Thursday, July 07, 2016 12:16:50 PM
at least for awhile:
http://investor.cellectarbiosciences.com/releasedetail.cfm?releaseid=948767
Notice that the first cohort of Clinical Trial lasted 85 days, and that the second cohort likely started in Febuary 2016 with the higher dosage. Phase 2 clinical trials will start at the end of summer after the results are announced for Part Two of the Phase One trials now completing. IMHO
THIS IN MY OPINION IS THE AREA WHERE WE CRUSH THE $4 TRADING RANGE. I HAVE NO OPINION WHERE THE NEW TRADING RANGE WILL BE, BUT TRY LOOKING AT A TWO OR THREE YEAR PRICE CHART OF CLRB TO SEE THE POTENTIAL RANGES. IT IS VERY BULLISH!
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=CLRB
Note: The early January price spike broke $10 on the 1-5-16 news linked above.
Recent CLRB News
- Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides • GlobeNewswire Inc. • 05/29/2024 10:40:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 08:46:56 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/16/2024 10:05:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 10:45:17 AM
- Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 05/14/2024 10:40:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:32:20 AM
- Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day • GlobeNewswire Inc. • 05/08/2024 10:40:23 AM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 10:40:00 AM
- Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2024 10:40:00 AM
- Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 10:40:00 AM
- Cellectar Biosciences to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/14/2024 12:52:48 PM
- Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer • GlobeNewswire Inc. • 03/04/2024 11:40:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:31:57 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:29:43 PM
- Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:03:04 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/31/2024 01:00:28 PM
- Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study • GlobeNewswire Inc. • 01/30/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:30:40 PM
- Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million • GlobeNewswire Inc. • 01/25/2024 11:40:00 AM
- Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient • GlobeNewswire Inc. • 01/22/2024 11:40:00 AM
- Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data • GlobeNewswire Inc. • 01/16/2024 11:40:00 AM
- Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results • GlobeNewswire Inc. • 01/12/2024 11:44:16 AM
- Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting • GlobeNewswire Inc. • 01/11/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 11:02:18 AM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM